Tumor-associated vasculature is a relatively accessible component of solid cancers that is essential for tumor survival and growth, providing a vulnerable target for cancer gene therapy administered by intravenous injection. Several features of tumor-associated vasculature are different from normal vasculature, including overexpression of receptors for angiogenic growth factors, markers of vasculogenesis, upregulation of coagulation cascades, aberrant expression of adhesion molecules and molecular consequences of hypoxia. Many of these differences provide candidate targets for tumor-selective 'transductional targeting' of genetically-or chemically modified vectors and upregulated gene expression can also enable 'transcriptional targeting', regulating tumor endothelia-selective expression of transgenes following nonspecific gene delivery. Tumor vasculature also represents an important site of therapeutic action by the secreted products of antiangiogenic gene therapies that are expressed in non-endothelial cells. In this review we assess the challenges faced and the vectors that may be suitable for gene delivery to exploit these targets. We also overview some of the strategies that have been developed to date and highlight the most promising areas of research.
Introduction
Most cancer deaths result from metastatic disease, often with deposits of tumor disseminated widely around the body. Effective treatments must be capable of destroying these metastatic growths, necessitating development of pharmacological agents capable of reaching dispersed tumors following intravenous injection. It is therefore important that gene therapies for metastatic cancer are not inactivated by components of the blood stream nor rapidly sequestered into non-target tissues. In addition, there are challenging anatomical restrictions on gaining access to tumor cells, where limited fluid convection within solid tumors often restricts agents to diffusionbased penetration through the tumor stroma. For macromolecular agents such as gene vectors, whose diffusion is severely restricted, access is often limited to perivascular regions. In fact, the first cells encountered by gene delivery vectors entering solid tumors are the tumorassociated vascular endothelial cells. Accordingly, these cells represent intriguing therapeutic targets for cancer gene therapy simply on the basis of anatomical accessibility. Although they are not themselves tumor cells, tumor-associated vascular endothelia appear to provide an 'Achilles heel' for rational cancer gene therapy. In this review, we assess the various ways that the tumorassociated vasculature can be used to gain anticancer activity, and discuss factors that limit present technologies and how they may be overcome.
Distinguishing features of tumour endothelium
Tumor vasculature differs from normal vessels in many ways 1 and these provide a variety of pathways for selective targeting of gene therapy ( Figure 1 ). One notable example is angiogenesis, the process of developing new blood vessels from pre-existing vasculature. Angiogenesis occurs only rarely in the normal human adult, being restricted to the menstrual cycle, wound healing, embryonic development and in various disease pathologies. Tumor angiogenesis is now well recognized as a critical hallmark of cancer, 2 essential for the growth of primary and secondary tumors and a key component of the mechanisms of metastasis.
Tumor angiogenic vessels have many differences from normal vessels. They are disorganised, leaky with blind end loops and are often hypoxic. They have abnormal pericyte coverage and relatively little muscle coverage. 3 Thus, their microenvironment is substantially different from normal vessels. Clearly, angiogenic vessels are proliferating more rapidly than normal vessels and this is mainly driven by vascular endothelial growth factor (VEGF). VEGF receptors 1, 2 and 3 may all be upregulated on tumor vessels as is a VEGF co-receptor Neuropilin 1. 4 Endoglin, a co-receptor for the transforming growth factorb (TGFb) is also upregulated. Other receptors that play an important role in tumor-associated angiogenesis also provide targets for therapeutic intervention, for example TIE1 and TIE2, which are involved in vascular differentiation. Several mechanisms have been described recently, whereby tumors may gain improved vascular supply, besides endothelial proliferation and migration (angiogenesis), and all these provide molecular opportunities for selective intervention using gene therapy. These include vasculogenesis, vascular co-option, intussusception 5 and vascular mimicry. 6 Probably, the most significant finding relates to vasculogenesis, a process in which endothelial progenitor cells (EPCs) from the bone marrow (BM) are recruited into the tumor bed accelerating vascular growth. 7, 8 These endothelial cells have defining markers such as CD133 and have recently been shown in the vessels of human lung tumors and vessels of tumors in human transplant recipients. 9, 10 The majority of work in this area relates to animal models, where inhibition of this cell population has been shown to inhibit tumor growth. In addition, because the endothelial progenitor cells target vasculature, they have been investigated as cellular vectors for delivery of gene therapy. The process of homing of EPCs to tumor vasculature includes expression of pathways induced by hypoxia such as CXCR4 and its ligand SDF1, 11 also a hypoxia induced protein.
Tumor-associated hypoxia also provides other targets related to both tumor cells and tumor vasculature. A key element in mediating effects of hypoxia is hypoxia inducible factor 1a (HIF1a), a heterodimer involving HIF1a and ARNT, the aryl hydrocarbon nuclear translocator. 12 This binds specific hypoxia response elements (HRE) of approximately 200 genes, which are critical in the angiogenic response and survival under hypoxia conditions. HIF1a is degraded in normoxic conditions after prolyl hydroxylation via a family of prolyl hydroxylases. The modified HIF1a interacts with the von Hippel Lindau protein, VHL, which targets it for destruction in the proteasome by ubiquitination. As oxygen tension drops, there is less modification of the prolyl residues and the HIF is then stabilized. HIF is also a target for many small molecule inhibitors, but very high specific induction of genes by the HRE provides a direct method of gene regulation in the hypoxia zone of tumors, reflecting a major physiological difference between tumor and normal cells. Some of the pathways regulated by hypoxia have already been described above, for example, Neuropilin 1, VEGF receptor 1 and endoglin, but others are also induced, such as PAI1 and adrenomedullin. 13 Other characteristics of the tumor vasculature can also be used as targets. For example, adhesion molecules induced partly by inflammatory cytokines and also by angiogenic factors are often upregulated in tumor vasculature, including aVb3 and aVb5 integrins.
14 Other cell adhesion proteins, which are subject to differential splicing in development, such as fibronectin and its splice variant EDB show upregulation of the earlier form in tumor vessels. 15 Tenascin-C, an extracellular matrix glycoprotein similarly shows splice variants, with the C domain being expressed in cancer.
Tumor-associated vasculature also shows activation of coagulation and proteolysis pathways, with upregulation of tissue factor 16 and urokinase receptors. 17 These proteins are upstream of complex proteolytic cascades. The leakiness of tumor vessels induced by VEGF allows extensive diffusion of fibrin 18 and other proteins of the coagulation cascade into the extracellular matrix. Thus, the stroma around vessels differs from the normal, as does vascular access. Because of poor fluid convection through tumor interstitium, the interstitial pressure is often higher in tumors than normal tissues, which may favor trapping of delivery platforms.
Therapeutic modalities

Antiangiogenic strategies
The discovery of antiangiogenic molecules regulating proliferation and maintaining quiescence of normal endothelium provides a particularly enticing range of proteins and peptides suitable as therapeutic mediators. 19 Among the earliest discovered were angiostatin and endostatin, proteolytic degradation products of plasminogen and collagen XVIII, respectively. In addition, the soluble extracellular forms of receptors able to bind angiogenic factors, or peptide angiogenic inhibitors, are key effector molecules that can be used to inhibit angiogenesis via gene therapy.
Gene-directed enzyme-prodrug therapy (GDEPT)
This approach involves the expression of an enzyme within target cells that is capable of activating a non-toxic prodrug to a potent cytotoxic species, leading to death of the cell producing the enzyme and ideally destroying surrounding cells (known as the 'bystander effect') ( Figure 1 ). Examples include the Escherichia coli enzyme nitroreductase (NTR), which activates the prodrug CB1954 to produce a bifunctional alkylating agent, 20 and thymidine kinase (HSV-TK) from Herpes simplex, which activates the prodrug gancyclovir (GCV) to a toxic antimetabolite.
Direct cytotoxicity
Several gene products can be directly cytotoxic, and these may kill tumor vascular endothelium directly and independent of cell cycle. Examples include ricin A chain and the A chain of diphtheria toxin. 21 Expression of procoagulant activity It is possible to express procoagulant molecules (e.g. tissue factor) selectively within tumors, leading to local blood clotting that can inhibit supply of nutrients and oxygen to tumor cells (Figure 1 ). This strategy is particularly attractive as it avoids the need for therapeutic agents to transduce large numbers of tumor or endothelial cells, as the therapeutic mechanism is extracellularly effective. Nevertheless, safe and effective use of this approach is highly dependent on finding a strategy that efficiently discriminates between normal and tumorassociated vasculature. 22 
Virotherapy
Conditionally replicating viruses can be designed to replicate selectively within tumor-associated vasculature, depending on the availability of specific transcription factors. This leads to lytic cell death and spread of the virus to adjacent endothelial cells and tumor cells.
Transductional targeting to tumor endothelium
Prerequisites to enable targeting to disseminated tumor metastases Efficient delivery and expression of therapeutic transgenes within tumor-associated vasculature requires delivery of the gene vector via the bloodstream, an environment well equipped to destroy microorganisms and other particulates as part of the body's defence against infection. 23 Successful vectors must be able to survive in this harsh environment, ideally achieving extended plasma circulation kinetics in order to allow them to gain access to disseminated cancers. Unfortunately, following intravenous injection, most viral vectors are cleared very rapidly into the liver, predominantly via nonspecific phagocytosis by hepatic Kupffer cells. This provides a major barrier to gaining efficient bloodborne delivery of viruses to peripheral targets, even for viruses that have their active tropisms ablated (see below).
Several strategies are being developed to overcome unwanted phagocytic clearance, including the use of stealth (polymer coated) vectors, 24 ablation of Kupffer cells using bisphosphonate (clodronate) liposomes 25 or a poorly defined predosing strategy that appears to downregulate phagocytic clearance and enables improved circulation of the second dose. 26 It is worth noting that most vectors do not transduce Kupffer cells; hence, analysis of transgene expression gives a very incomplete picture of virus distribution. As toxicities are normally associated with vector particles, rather than transgene expression, this remains an important issue that must be resolved.
Many viral vectors have an intrinsic tropism for infection of non-target cells, for example type 5 adenovirus (Ad5) efficiently infects murine hepatocytes following intravenous injection. Apart from leading to rapid loss of vector, limiting the amount available for systemic distribution, this may also induce undesirable side effects such as toxicity in the liver owing to unwanted transgene expression. 27 Vectors capable of efficient delivery to tumor-associated vasculature must therefore usually be 'detargeted' in order to permit their persistence in the bloodstream sufficiently to enable access to target sites, and also 'retargeted' to enable infection of their intended target cells and tissues (Table 1) .
Genetic detargeting and retargeting strategies
It is an attractive notion to modify the tropism of viruses genetically, eliminating their normal tropisms and potentially introducing new ones. Several genetic attempts have been made to detarget adenovirus 5 from murine liver, by ablating CAR-binding, integrin-binding and heparin sulfate proteoglycan-binding sites. 28, 29 Results have varied between different groups. However, the net results show that some detargeting can be achieved using genetic modifications, although the variety of infection pathways operative in vivo makes this less successful than expected. In addition, the changes introduced are heritable. Accordingly, very careful consideration must be given to the possibilities of recombination in vivo that could yield replication competent forms, potentially with new patterns of infection.
Small peptides are of particular interest as ligands because they offer the possibility of genetic retargeting without affecting the overall structure of viral proteins in which peptides are inserted. The peptide ligand most widely used to date is an RGD peptide that retargets to aVb3 integrins, but some other peptides have been used to target unknown receptors on vascular endothelium (see below).
The genetic insertion of RGD sequence into viral genome has been performed in adenovirus and adenoassociated virus (AAV). Adenoviral RGD sequence insertion has been performed into the HI loop of adenovirus fiber to ablate natural CAR binding and enhance vasculature targeting. This RGD insertion has been proven to increase transduction of human saphenous vein endothelial cells and primary human endothelial cells, but showed similar transduction in human umbilical vein endothelium cells (HUVEC) to wild-type virus. 30, 31, 32 For AAV-2 that naturally infects cells via heparan sulfate proteoglycan receptor (HSPG), the RGD insertion was successfully performed at viral VP3 sites. This RGD insertion enabled infection of integrin-expressing cancer cells independently of HSPG without ablating normal tropism, 33, 34 and this may increase the ability of the virus to infect endothelial cells.
Peptides identified by phage display have been genetically inserted into genes encoding viral surface proteins in order to target vascular endothelium, but the receptor they bind is unknown. For example, MTPFPTSNEANL was introduced into the AAV-2 capsid to reduce natural binding to HSPG and increase targeting to vascular endothelial cells. In vivo this retargeted virus showed extended plasma circulation, less liver virus accumulation and 2.5 times more efficient targeting than wild-type virus to venous endothelial cells from vena cava. 35 SIGYPLP is a small peptide that was introduced into the HI loop of the adenovirus fiber and mediated increased targeting to endothelial cells such as HUVEC and human saphenous vein endothelial cells. 36 Physical detargeting and retargeting strategies A simpler and potentially safer strategy to detargeting involves coating the surface of viruses using reactive Abbreviations: AAV, adeno-associated virus; GFP, green fluorescent protein; PEI: polyethylenimine; PEG; polyethylene glycol.
Gene therapy against tumor vasculature M Bazan-Peregrino et al hydrophilic polymers such as polyethylene glycol (PEG) 37 to ablate normal tropisms, with the pattern of infectivity subsequently expanded following attachment of a new ligand. 38 These methods are not transmittable decreasing safety concerns and by forming a physical barrier around the virus they provide nonspecific protection from receptors (many as yet unknown) as well as anti-adenovirus antibodies. Adenovirus coated with multivalent reactive polymers based on poly[N-(2-hydroxypropyl)methacrylamide] (pHPMA) show particularly good ablation of normal receptor binding 39 and extended plasma circulation following intravenous injection. 24 This provides an interesting platform for receptor-specific retargeting following introduction of new ligands. For example, using pHPMA for coating adenovirus and retargeting with VEGF gave extended blood circulation and selective infectivity to HUVEC cells in co-culture of HUVEC and CAR-expressing SUIT2 cells. 39 SIGYPLP peptide was also used in detargeting/retargeting systems using pHPMA vectors in non-viral and adenoviral gene delivery. 40 However, the efficiency of targeting to tumor vasculature with these vectors has yet to be evaluated.
Synthetic insertion of RGD peptide onto the surface of non-viral vectors or viruses via polymers has also shown increased binding to tumor endothelium. Non-viral vectors such as liposomes or nanoparticles (NP) do not have an active tropism, but can be targeted via PEG conjugated to RGD. For example, NP based on PEGylated polyethyleneimine (PEI) coupled with RGD peptide were used to deliver VEGFR2-siRNA intravenously, inhibiting VEGFR2 expression, tumor growth and angiogenesis. 41 Another NP targeted to integrins was achieved with the use of cationic polymerized lipids and a small integrin avb3-targeting ligand (avb3-NP). This vector delivered a mutant Raf-1 gene (which disrupts pRb signalling, inhibiting cell proliferation and VEGFmediated capillary tubule formation 42 ) leading to apoptosis of tumor vasculature, regression of primary tumors and inhibition of lung metastasis. 43 Adenovirus has also been retargeted with RGD peptides via PEG showing increased blood circulation and enhanced transgene expression in activated vascular endothelial cells. 44 
Pseudotyping of viral vectors
Pseudotyping is the process of changing the natural tropism of a virus to that of another virus by switching their surface proteins. For example, AAV is frequently retargeted by pseudotyping, using capsids from different AAV serotypes. However, as AAV-2, the most common vector, is already the most infectious to HUVEC 45, 46 pseudotyping of AAV is unlikely to improve endothelial targeting. In contrast, the vascular selectivity of Ad5 (the most commonly used adenovirus serotype) can be increased by pseudotyping with fiber from subgroup B adenovirus 16. Retargeting in this way (mainly via CD46 47 ) improves Ad5 vascular transduction, including in human saphenous vein ex vivo and human umbilical vein endothelial cells in vitro. 48 It is also known that subgroup B adenoviruses show lower infection of murine hepatocytes in vivo than Ad5, decreasing clearance and facilitating retargeting to peripheral sites. 49 Lentivirus has intrinsically low endothelial infectivity, but is commonly pseudotyped with a variety of nonretroviral glycoproteins derived from other viruses such as vesiculoviruses (VSV), lyssaviruses, hepadnaviridae, flaviviridae, paramyxoviridae, orthomyxoviruses, filoviruses and alphaviruses. 50 However, to date, it is not clear if any of these pseudotyped lentiviruses can target endothelium more selectively. 51 Retargeting using antibodies Antibodies can be used to bind specific receptors on tumor vasculature to enable specific targeting of vectors. One strategy is the use of bifunctional antibodies that bind both the adenoviral capsid and a tumor vasculatureassociated epitope. For example, an antibody recognising both the adenovirus fiber and endoglin-mediated adenovirus entry to HUVEC cells via endoglin. However this antibody-linked virus was not detargeted and could still infect other cells via CAR. 52 Genetic modification on the envelope of moloney murine leukemia virus to insert a sequence for an IgG-binding peptide (protein A) can enable this virus to bind any antibody and be retargeted. For example, with the use of an anti-Flk-1/KDR, this type of retroviral vector could be targeted to activated endothelial cells. 53 In a different strategy, when polymers are used to coat the virus it may be retargeted with antibodies. For example, conjugation of PEG onto the adenovirus surface and linking E-selectin-specific antibody has shown longer blood circulation and enhanced transgene expression in activated vascular endothelial cells. 44 
Transcriptional targeting to tumor endothelium
Some genes are expressed differentially in tumor vasculature, compared to normal vasculature (see earlier). Accordingly, selective expression of therapeutic transgenes can be achieved by placing the transgenes under the control of tumor vasculature-associated promoters (Figure 1) . These promoters are regulated by transcription factors that are overexpressed in tumor-associated vasculature. For example, native promoters of endoglin, endothelin-1, VEGF, pro-endothelin-1, ICAM-2, Flt-1 and KDR can all be used to direct transcription of GDEPT-genes, antiangiogenic factors, apoptotic inducing proteins or key viral genes for virotherapy (Table 2) .
Some studies have sought to identify the most useful tumor endothelial-selective promoters for therapeutic use. For example, combining retroviral hybrid LTR with endothelial promoters, including Flt-1, ICAM-2 or KDR, showed good selectivity in tumor endothelium in vivo, with LTR-ICAM-2 promoter showing the greatest specificity. 54 Another study compared the endothelial specificity of several promoters including Tie1, Tie2, Flk-1, vascular endothelial (VE)-cadherin and ICAM-2 in selfinactivating lentiviral vectors using a variety of primary cultures and cell lines. It was found that Tie2 promoter/ enhancer sequences were more endothelial-specific. 55 Regarding hypoxia-inducible promoters, VEGF promoter seems to enhance transcription more efficiently under hypoxic conditions than the erythropoietin promoter. 56 Endothelial transcription of GDEPT A number of viral vectors have used endothelial-specific transcription to deliver GDEPT-genes for destruction of tumor vasculature. Delivering HSV-TK/GCV therapy to tumor vasculature with different types of vectors has shown promising results. For example, a retroviral vector with hybrid LTR and prepro-endothelin-1 promoter expressing HSV-TK-induced vascular disruption, tumor growth inhibition and survival increment upon treatment with GCV. 57 Another retroviral vector expressing HSV-TK regulated by the promoter of VEGF containing HREs was directly transfected into cancer cells, and shown to inhibit tumor growth. 58 This type of vector could equally be used in tumour endothelial cells (Figure 1 ). Adenoviral expression of HSV-TK under the control of VE-cadherin promoter in vivo inhibited tumor growth and tumor vascular density. 59 Another adenovirus expressing HSV-TK under the control of an optimized hypoxia responsive promoter (OBHRE) derived from phosphoglycerate kinase 1 promoter is well tolerated in liver after intravenous administration contrary to administration of Ad.CMV-TK/GCV. 60 In addition, an adenoviral vector simultaneously expressing both cytosine deaminase (CD) and HSV-TK genes under the transcriptional control of KDR promoter showed that this combined CD/TK therapy is more effective at killing HUVEC than with either treatment alone. 61 Von Willebrand factor (vWf) promoter has also been employed to drive the transcription of HSV-TK, showing endothelial selectivity, but with low activity. 62 However, whether the vWf promoter is upregulated in tumor endothelium is not clear.
Other GDEPT-genes that have been transcriptionally regulated to target tumor endothelium include NTR and cytochrome P450-CYP2B6. Lentiviral delivery of NTR under the control of Tie2 promoter/enhancer induced conditional cytotoxicity only in endothelial cells and its systemic delivery specifically targeted tumor endothelium. 55 5xHREs of VEGF promoter were employed to drive the regulation of NTR, delaying tumor growth of transfected cancer cells, but this plasmid was only delivered to cells before transplantation to mice, so there is a need to develop a vector. 63 Finally, an adenovirus expressing cytochrome P450-CYP2B6 regulated by the optimized hypoxia responsive promoter together with cyclophosphamide showed an ability to delay tumor growth. 60 Endothelial transcription of pro-apoptotic proteins Destroying tumor vasculature with pro-apoptotic genes can be selectively achieved with the use of tumor vascular- Abbreviations: CD, cytosine deaminase; GDEPT, gene-directed enzyme-prodrug therapy; GFP, green fluorescent protein; HSV-TK, thymidine kinase; NTR, nitroreductase; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; VSV, vesiculoviruses. associated promoters. For example, the modified promoter of prepro-endothelin-1 was used to drive the expression of a chimeric death receptor that includes both the extracellular portion of TNFR1 and the transmembrane/ intracellular region of Fas. This adenoviral vectorimpaired tumor vessels, reduced metastatic mass and slowed tumor growth. 64 Tumor necrosis factor-a has been placed under the control of KDR and E-selectin promoters in retroviral vectors, demonstrating that its expression is selective but low in endothelial cells. 65 An adenoviral vector expressing an inducible Caspase-9 under the regulation of VEGFR2 promoter showed endothelial cell apoptosis in vitro and substantial decrease in tissue microvessel density when co-delivered with its inducer AP20187 drug. 66 Diphtheria toxin A chain has been placed under E-selectin promoter to make its toxicity selective to tumor endothelium. 21 However, its delivery has yet to be addressed as this plasmid-expressing DT-A was delivered via electroporation in vitro.
Endothelial transcription of antiangiogenic proteins
Expression of antiangiogenic factors within tumor endothelium should produce a localized anti-angiogenic environment within tumor vasculature. For example, sFlk-1 has been placed under the control of 10 Â HRE within a HSV-amplicon and therefore can be expressed within any hypoxic cell including endothelial and tumor cells. This vector showed significant capillary inhibition in vitro and inhibition of tumor growth in vivo.
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Virotherapy using tumor vasculature-selective promoters Virotherapy was originally designed to kill cancer cells only leaving normal cells alive. However, destruction of normal vasculature associated with tumor can be achieved by placing key viral genes under the control of tumor endothelial-associated promoters. For example, Flk-1 enhancer/promoter and endoglin promoter have been used to drive the transcription of adenoviral E1A and E1B genes, respectively. Both conditionally replicating adenoviruses (CRAd) are selective for replication within dividing endothelial cells, disrupting capillary-like structures in vitro, with efficiency levels compared to those of wild-type adenovirus. 68 Other CRAds that have HREs regulating E1A region, replicate selectively in cancer cells under hypoxia and VHL mutant cells, and could potentially kill hypoxic tumor-associated vasculature. 69, 70 However, enhanced activity against tumor vasculature has yet to be proven, with murine models generally regarded as unsuitable for study because mouse endothelium does not allow adenoviral replication.
Combining transductional and transcriptional targeting
In principle, combination of transductional and transcriptional targeting should allow a higher selectivity against tumor vasculature. Two studies addressing this possibility use adenovirus vectors to take advantage of RGD-mediated transductional targeting and Flt-1 transcriptional targeting. In the first study, only reporter gene expression from a non-replicating adenovirus was studied, 71 while the second study reported the use of a CRAd to mediate significant inhibition of tumor growth in vivo. This CRAd had E1A expression under the control of Flt-1 promoter, was retargeted with RGD in the HI loop and expressed mda-7/IL24 gene (a pro-apoptotic and antiangiogenic gene) and was interpreted to act via murine endothelium. 72 
Antiangiogenic gene therapy expressed in non-endothelial cells
Therapeutic genes with antiangiogenic function may also be expressed within non-endothelial cells, providing a cell 'factory' secreting active proteins into the circulation. Although the same effects could be achieved, at least in principle, by intravenous injection of recombinant proteins, the gene therapy approach is likely to be more costeffective, proteins are likely to be more appropriately glycosylated and potentially less immunogenic, and duration of action will be extended by continuous production of protein in situ replenishing the circulating pool. Antiangiogenic factors are already showing particular promise from a cell factory approach. With this strategy, a variety of viral and non-viral vectors have been designed to deliver many antiangiogenic genes and several of them have shown significant anti-tumor effect.
Transcription of antiangiogenic factors from endothelial-targeted AAV has not led to measurable anticancer activity to date. However, if AAV transcription is directed from tumour or liver, then considerable antiangiogenic activity is achieved. Antiangiogenic genes successfully delivered using AAV in this way have included secreted forms of angiostatin and endostatin, 73 Flk-1 74 and TIMP-1. 75 Synergistic effects have been observed with angiostatin and endostatin. 73 Long-term expression is a desirable characteristic for the production of antiangiogenic factors from a cell factory, and lentivirus is the obvious vector. Again, endothelial directed expression has not shown significant therapeutic effectiveness using lentivirus. 51 However, infection of non-endothelial cells and lentivirus-mediated transcription of anti-angiogenic factors such as endostatin, 76 TIMP-3 46 or PEX, a non-catalytic fragment of MMP-2, 77 leads to a significant reduction of tumorassociated vasculature.
Adenoviruses can infect many types of cells and, therefore, represent a versatile vector for the delivery of antiangiogenic factors. Examples include TIMP-3, 78 angiostatin, endostatin, 79 platelet factor-4, 80 thrombospondin-1, 81 soluble extracellular domains of growth factor receptors such as Flt-1 82 and FGF-R 83, including fusion proteins containing the Fc portion of antibodies such as Flk1-Fc, 79 sNeuropilin-1-Fc, 84 and intrabodies that block Tie-2 receptor surface expression. 85 All these anti-tumour angiogenesis strategies using adenovirus as a vector showed a significant reduction in tumor angiogenesis and tumor growth, except for endostatin and angiostatin. 79 Combination of antiangiogenic factors has shown synergistic effects. 80 Non-viral vectors such as liposomes that do not have a natural target and can transduce many cell types have been also employed as vectors for anti-angiogenic gene delivery. A variety of genes encoded within plasmids have been delivered using liposomes including angiostatin, endostatin, TIMP-2, 86 Thrombospondin-1 87 and a snake venom-derived disintegrin called salmosin. 88 This strategy has demonstrated reduction in tumor size and number of metastases in mice.
There are a number of recently identified proteins that show antiangiogenic effects, most notably Fibulins and VEGI. Fibulins 5 and 3 appear to inhibit angiogenic sprouting and MMP activity, possibly through stimulation of TIMPs. 89 VEGI is a member of the tumor necrosis factor family that is thought to be an endogenous inhibitor of angiogenesis and tumor growth. 90 Blocking angiogenic factors with the use of siRNA or antibodies could inhibit angiogenesis. For example, inhibition of expression of Syndecan-2 with siRNA inhibits angiogenesis in vitro. 91 These types of proteins should be explored with a feasible gene delivery vector.
Cellular vectors targeting tumor vasculature
Cellular vectors can also be used to deliver genetic therapy to tumor vasculature, most notably stem cells. It is not clear what fraction of bone marrow-derived endothelial precursor cells contribute to tumor angiogenesis, but some studies have shown the potential use of genetically modifed stem cells to target tumor vasculature. For example, a suicide gene was targeted to tumor angiogenic vasculature by transplanting ex vivo genetically modified hematopoietic stem cells. 92 These cells were transduced with a lentivirus expressing HSV-TK under the regulation of Tie2/Tek promoter. When transplanted into tumorbearing mice, these BM cells homed to the tumor and interacted closely with vascular endothelial cells at the tumor periphery, but they did not differentiate into endothelial cells. If this transplanted Tie2/HSV-TK BM cells were given GCV, selective elimination of Tie2-expressing mononuclear cells was achieved together with substantial inhibition of angiogenesis and slow tumor growth. Another antiangiogenic strategy involved the insertion of a soluble truncated form of Flk-1 into BMderived cells via a retroviral vector without a tissuespecific transcriptional regulation. After 3 months of BM transplantation, tumor growth was significantly inhibited; however, this antiangiogenic effect may come from a paracrine rather than an autocrine effect. 93 Neural stem cells track glioma cells that have moved away from initial tumor site. A PEX-expressing human neural stem cell line was injected into an established glioma tumor in nude mice. These cells showed migration to the tumor boundary and reduced tumor volume by 90% showing decreased angiogenesis. 94 
Identification of new targets
Several novel approaches have been taken to isolate new pathways involved in angiogenesis, particularly focusing on proteins expressed on cell membranes. These include using in vivo perfusion of tumor-bearing rodents with silica beads, which strip membrane proteins and then attach to the beads. Purification of membrane proteins is then followed by proteome analysis. This approach has been used to reveal the transferrin receptor is upregulated in tumor endothelium in the lung. 95 Serial analysis of gene expression (SAGE) from micro dissected blood vessels from primary colon tumors led to the discovery of several tumor endothelial markers (TEMs). 96 Mouse equivalents have since been defined, most particularly for TEMs 1, 5 and 8. 97 Bio-informatic approaches, using extensive public array and sequence data, have shown several endothelial-specific cell surface adhesion molecules, for example, ROBO4, Delta 4 and endosialin (TEM1). 98 The definition of these pathways and the key growth factor pathways regulating angiogenesis have provided the basis for gene therapy approaches.
At present, the main cell types that have been targeted in the tumor vasculature are endothelial cells and stem cells. However, tumor vasculature also includes pericytes (PCs) and smooth muscle cells that could form important targets. In addition, tumor stroma contributes towards an angiogenic phenotype, for example, fibroblasts found within tumor vasculature show unusually high levels of PDGFRb and stromal cell-derived factor-1a, 99 ,100 as well as proteins involved in lactate absorption (MCT1/MCT2) and lactate oxidation (high LDH1 and low HIFa/LDH5). 101 These upregulated genes may provide useful transcriptional regulation for expression for therapeutic genes within these cells.
Improvements in our understanding of tumor vasculature are leading to the identification of promising targets for molecular intervention using gene therapy, employing therapeutic strategies mechanistically distinct from conventional cancer chemotherapy. Given the selectivity of these approaches the patterns of side effects engendered may be different and less severe than with established treatments. Accordingly, it may be realistic and very beneficial to consider combining these different treatment modalities. In addition, most of the vascular targets have the advantage that they are readily accessible from the bloodstream, raising the possibility of systemic delivery of therapeutic genes to disseminate tumor masses. Now that antiangiogenic therapy is a proven strategy with established drugs, the possibilities of using gene therapy to achieve more selective and localised therapeutic effects are very enticing.
